{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:06:30Z","timestamp":1789776390185,"version":"4.0.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.vaccine.2026.128437","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:57:02Z","timestamp":1773251822000},"page":"128437","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A narrative review of immune-mediated adverse events in clinical trials of CpG oligonucleotide toll-like receptor 9 agonists"],"prefix":"10.1016","volume":"79","author":[{"given":"Robert S.","family":"Janssen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Coffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128437_bb0005","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging concepts in the science of vaccine adjuvants","volume":"20","author":"Pulendran","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.vaccine.2026.128437_bb0010","doi-asserted-by":"crossref","first-page":"6630","DOI":"10.1016\/j.vaccine.2008.09.049","article-title":"Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines","volume":"26","author":"Verstraeten","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128437_bb0015","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11910-018-0851-5","article-title":"Narcolepsy associated with pandemrix vaccine","volume":"18","author":"Sarkanen","year":"2018","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.vaccine.2026.128437_bb0020","doi-asserted-by":"crossref","first-page":"6202","DOI":"10.1016\/j.vaccine.2018.08.008","article-title":"Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines - multi-country assessment","volume":"36","author":"Weibel","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128437_bb0025","doi-asserted-by":"crossref","first-page":"E12323","DOI":"10.1073\/pnas.1818150116","article-title":"Autoimmunity to hypocretin and molecular mimicry to flu in type 1 narcolepsy","volume":"115","author":"Luo","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2026.128437_bb0030","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1016\/j.vaccine.2012.01.087","volume":"30","author":"Halperin","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128437_bb0035","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1016\/j.vaccine.2018.03.067","article-title":"Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant in adults","volume":"36","author":"Hyer","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128437_bb0040","series-title":"HEPLISAV-B FDA approval letter ed","first-page":"8","article-title":"HEPLISAV-B FDA approval letter","author":"US Food & Drug Administration","year":"2017"},{"key":"10.1016\/j.vaccine.2026.128437_bb0045","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1016\/j.vaccine.2023.06.004","article-title":"Post-licensure safety study of new-onset immune-mediated diseases, herpes zoster, and anaphylaxis in adult recipients of HepB-CpG vaccine versus HepB-alum vaccine","volume":"41","author":"Ackerson","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128437_bb0050","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.4161\/hv.24256","article-title":"Immunogenicity of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in nonresponders to licensed hepatitis B vaccine","volume":"9","author":"Halperin","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.128437_bb0055","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.vaccine.2017.12.038","article-title":"Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults","volume":"36","author":"Jackson","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128437_bb0060","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1016\/j.vaccine.2012.02.001","article-title":"Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine","volume":"30","author":"Sablan","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128437_bb0065","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0140-6736(22)00055-1","article-title":"Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial","volume":"399","author":"Bravo","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128437_bb0070","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/S1473-3099(22)00144-X","article-title":"Impact of previous exposure to SARS-CoV-2 and of S-trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial","volume":"22","author":"Smolenov","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128437_bb0075","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.vaccine.2023.02.017","article-title":"Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-na\u00efve and exposed individuals in a phase 2\/3, double-blind, randomized study","volume":"41","author":"Buntinx","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128437_bb0080","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1016\/j.vaccine.2023.02.018","article-title":"Six-month safety follow-up of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in adults: a phase 2\/3, double-blind, randomized study","volume":"41","author":"Hosain","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128437_bb0085","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2206359","article-title":"Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12-17 year-old adolescents","volume":"19","author":"Lopez","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.128437_bb0090","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1016\/S1473-3099(22)00502-3","article-title":"Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial","volume":"22","author":"Lazarus","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128437_bb0095","first-page":"242","volume":"87","author":"Taucher","year":"2023","journal-title":"J Inf Secur"},{"key":"10.1016\/j.vaccine.2026.128437_bb0100","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.vaccine.2022.10.030","article-title":"An evaluation of the safety and immunogenicity of MVC-COV1901: results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay","volume":"41","author":"Torales","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128437_bb0105","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2203632","article-title":"Immunogenicity and safety of biological E\u2019s CORBEVAX\u2122 vaccine compared to COVISHIELD\u2122 (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial","volume":"19","author":"Thuluva","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.128437_bb0110","article-title":"Safety and immunogenicity of booster doses of an XBB.1.5 RBD subunit COVID-19 vaccine among individuals aged 5-80 years in India: a phase 3, single-blind, randomised controlled trial","volume":"40","author":"Thuluva","year":"2025","journal-title":"Lancet Reg Health"},{"key":"10.1016\/j.vaccine.2026.128437_bb0115","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1016\/j.vaccine.2024.03.077","article-title":"Immunogenicity and safety of SARS-CoV-2 recombinant protein subunit vaccine (IndoVac) adjuvanted with alum and CpG 1018 in Indonesian adults: a phase 3, randomized, active-controlled, multicenter trial","volume":"42","author":"Nurdin","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128437_bb0120","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1158\/2159-8290.CD-18-0280","article-title":"SD-101 in combination with pembrolizumab in advanced melanoma: results of a phase 1b, multicenter study","volume":"8","author":"Ribas","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.vaccine.2026.128437_bb0125","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1158\/1078-0432.CCR-25-0987","article-title":"Phase 2, open-label, multicenter study of nelitolimod in combination with pembrolizumab in anti-PD-1 treatment-na\u00efve advanced melanoma","volume":"31","author":"Ribas","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2026.128437_bb0130","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1158\/1078-0432.CCR-21-1411","article-title":"Intralesional SD-101 in combination with pembrolizumab in anti-PD-1 treatment-na\u00efve head and neck squamous cell carcinoma: results from a multicenter, phase II trial","volume":"28","author":"Cohen","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2026.128437_bb0135","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1158\/2159-8290.CD-18-0743","article-title":"In situ vaccination with a TLR9 agonist and local low-dose radiation induces systemic responses in untreated indolent lymphoma","volume":"8","author":"Frank","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.vaccine.2026.128437_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26031235","article-title":"Targeting the PD-1\/PD-L1 signaling pathway for cancer therapy: focus on biomarkers","volume":"26","author":"Strati","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.vaccine.2026.128437_bb0145","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.vaccine.2026.128437_bb0150","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","article-title":"Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors","volume":"21","author":"Patnaik","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2026.128437_bb0155","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128437_bb0160","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.vaccine.2005.08.095","article-title":"Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults","volume":"24","author":"Halperin","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128437_bb0165","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0264-410X(03)00045-8","article-title":"A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant","volume":"21","author":"Halperin","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128437_bb0170","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1016\/j.vaccine.2013.05.068","article-title":"Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age","volume":"31","author":"Heyward","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128437_bb0175","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2016.4059","article-title":"Association of pembrolizumab with tumor response and survival among patients with advanced melanoma","volume":"315","author":"Ribas","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2026.128437_bb0180","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128437_bb0185","doi-asserted-by":"crossref","first-page":"6377","DOI":"10.1016\/j.vaccine.2014.06.065","article-title":"Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer","volume":"32","author":"Scheiermann","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128437_bb0190","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1080\/14760584.2024.2382725","article-title":"Adjuvant system AS01: from mode of action to effective vaccines","volume":"23","author":"Roman","year":"2024","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2026.128437_bb0195","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1016\/j.vaccine.2019.04.048","article-title":"Safety of AS03-adjuvanted influenza vaccines: a review of the evidence","volume":"37","author":"Cohet","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128437_bb0200","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1016\/j.vaccine.2008.03.093","article-title":"Safety of MF59 adjuvant","volume":"26","author":"Schultze","year":"2008","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26002458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26002458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:50:42Z","timestamp":1781308242000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26002458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":40,"alternative-id":["S0264410X26002458"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128437","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A narrative review of immune-mediated adverse events in clinical trials of CpG oligonucleotide toll-like receptor 9 agonists","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128437","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128437"}}